$0.15
+0.01 (+3.57%)
Open$0.15
Previous Close$0.14
Day High$0.15
Day Low$0.15
52W High$3.09
52W Low$0.05
Volume—
Avg Volume48.1K
Market Cap2.98M
P/E Ratio—
EPS$-2.81
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+27,575.9% upside
Current
$0.15
$0.15
Target
$40.13
$40.13
$29.11
$40.13 avg
$50.28
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 38.23M | 38.94M | 9.51M |
| Net Income | -52,587,129 | -48,215,582 | 434.3K |
| Profit Margin | -137.6% | -130.7% | 4.6% |
| EBITDA | -52,539,868 | -50,848,486 | 716.5K |
| Free Cash Flow | — | — | 350.1K |
| Rev Growth | -1.8% | -1.8% | +3.9% |
| Debt/Equity | 9.93 | 9.93 | 0.38 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |